Pantoprazole
| Evidence Level: L1 | Predicted Indications: 6 |
Table of Contents
Pantoprazole: From Gastro-oesophageal Reflux Disease to Active Peptic Ulcer Disease
One-Sentence Summary
Pantoprazole is a proton pump inhibitor originally used for acid-related conditions such as erosive oesophagitis and gastro-oesophageal reflux disease. The TxGNN model predicts it may be effective for Active Peptic Ulcer Disease, with 3 clinical trials and 19 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Erosive oesophagitis / gastro-oesophageal reflux disease (GORD) — standard proton pump inhibitor (PPI) class labelling |
| Predicted New Indication | Active Peptic Ulcer Disease |
| TxGNN Prediction Score | 99.69% |
| Evidence Level | L1 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, a fully documented mechanism of action record is not available for pantoprazole in this evidence pack. Based on the pharmacological information captured alongside the clinical evidence, pantoprazole is an irreversible proton pump (H+/K+-ATPase) inhibitor. It binds to the final common step of gastric acid secretion in the parietal cell, producing sustained suppression of acid output.
Acid suppression is the pharmacological cornerstone of both the original indication (erosive oesophagitis/GORD) and the predicted new indication (active peptic ulcer disease). Peptic ulcer healing depends on raising and maintaining intragastric pH above the threshold needed for mucosal repair and, where relevant, for antibiotic-based H. pylori eradication — a mechanism pantoprazole already exploits in its licensed acid-suppression role.
Because active peptic ulcer disease sits within the same acid-related disease spectrum as GORD, and because pantoprazole is already a recognised comparator/backbone agent in numerous peptic ulcer and H. pylori eradication trials, the TxGNN prediction is mechanistically coherent rather than speculative — it reflects an established class effect rather than an unrelated repurposing signal.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT02084420 | Phase 3 | Completed | 323 | Multicentre, randomised, double-blind, active-controlled comparison of ilaprazole vs pantoprazole triple therapy for H. pylori eradication in gastric and/or duodenal ulcer patients |
| NCT02197039 | N/A | Completed | 316 | Prospective study identifying risk factors for poor stigmata fading/early rebleeding after endoscopic haemostasis and high-dose PPI infusion in bleeding peptic ulcer, informing second-look endoscopy selection criteria |
| NCT00930670 | Phase 4 | Completed | 320 | Evaluation of PPI and statin influence on clopidogrel antiplatelet effect in patients undergoing PCI with dual antiplatelet therapy |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18824852 | 2008 | RCT | Digestion | Intermittent vs continuous pantoprazole infusion showed comparable efficacy in preventing peptic ulcer rebleeding after endoscopic therapy |
| 10632647 | 2000 | RCT | Alimentary Pharmacology & Therapeutics | Pantoprazole-based triple therapy (with amoxicillin and azithromycin/clarithromycin) for H. pylori eradication in duodenal ulcer |
| 16677158 | 2006 | RCT | Journal of Gastroenterology and Hepatology | Pantoprazole infusion as adjuvant to endoscopic treatment reduced rebleeding in peptic ulcer bleeding |
| 19938880 | 2009 | Review | Clinical Drug Investigation | Overview of pantoprazole pharmacology and efficacy; no clinically significant drug-drug interactions identified across numerous interaction studies |
| 38652367 | 2024 | Preclinical (animal) | Inflammopharmacology | Combined pantoprazole and mesenchymal stem cell therapy improved gastric ulcer healing via reduced oxidative stress, inflammation and apoptosis in a rat model |
| 12752349 | 2003 | Comparative study | Alimentary Pharmacology & Therapeutics | Comparison of three pantoprazole-based triple therapy regimens for H. pylori eradication and gastric ulcer healing |
| 15244210 | 2003 | Comparative study | Hepato-gastroenterology | Lansoprazole vs pantoprazole efficacy in active duodenal ulcer treatment and H. pylori eradication |
| 10228801 | 1999 | Clinical study | Hepato-gastroenterology | Rapid symptomatic improvement with pantoprazole plus amoxicillin and metronidazole in H. pylori-positive duodenal ulcer patients |
UK Market Information
Currently, no UK marketing authorisations are recorded in this evidence pack; the available data indicate pantoprazole is not marketed under the licences captured here.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The evidence level is L1, supported by multiple completed trials (including a Phase 3 multicentre RCT) and a substantial literature base directly evaluating pantoprazole in peptic-ulcer-related populations. The mechanism of action (irreversible H+/K+-ATPase inhibition) is directly relevant to acid-related ulcer healing, making the prediction pharmacologically coherent, though it should proceed under guardrails rather than unconditionally.
To proceed, the following is needed:
- Full UK/MHRA SmPC data (key warnings, contraindications, drug-drug interactions) — currently a blocking data gap for safety assessment
- Confirmed UK marketing authorisation and licensed indication status for pantoprazole
- Formal, structured mechanism-of-action documentation (original_moa) to support the mechanistic rationale beyond trial-derived inference
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.